Analysts set USD 21.50 target for Sotera Health stock
Analysts have set an average 12-month target of USD 21.50 for Sotera Health (SHC) stock, significantly above its current Nasdaq trading price. This comes as the company reported a 9.20% year-over-year revenue increase in Q2 2026 and improved operating profit. Sotera Health is also planning significant capital spending for compliance upgrades, Cobalt-60 development, and new sterilization capacity.
Sotera Health stock reports 9.2 percent revenue growth in Q2
Sotera Health (SHC) reported significant Q2 2026 results, with revenue growing 9.2% year-over-year to $321.375 million and net income soaring to $54 million from $8 million in the prior year. The company's adjusted EPS of $0.26 surpassed analyst expectations, and its stock was trading at $18.45 on Nasdaq, near its 52-week high. Analysts, like Piper Sandler, have reiterated an "Overweight" rating with a $25.00 price target, highlighting the company's strong performance in sterilization, laboratory testing, and advisory services.
Sotera Health (SHC) Looks Cheaper As Short Term Momentum Cools
Sotera Health (SHC) has seen its short-term momentum cool with a 6.25% share price drop over the past month, yet it still shows positive returns over 90 days and the past year. Despite the recent dip, analysts and intrinsic value estimates suggest the stock is undervalued, with a consensus target of $22.72 against its current trading price of $18.29. Investors are advised to consider underlying numbers and potential risks like ethylene oxide regulations.
Sotera Health Company (SHC) Stock Price, News, Quote & History
This article provides a comprehensive overview of Sotera Health Company (SHC), including its current stock price, historical performance, key financial metrics, and analyst ratings. It details the company's business segments: Sterigenics, Nordion, and Nelson Labs, which offer sterilization, lab testing, and advisory services. The report also highlights recent financial performance, earnings trends, and valuation measures.
Sotera Health Company Revenue Breakdown – LS:A2QHA5
Sotera Health Company (LS:A2QHA5) generated €990.73 million in revenue last year. Its top-performing segment, Sterigenics, contributed €643.49 million, while the United States was the largest regional contributor with €536.00 million. This data provides a breakdown of the company's revenue by segment and geography.
Sotera Health: Pricing Power And Recurring Revenues Are Growth Drivers (NASDAQ:SHC)
Sotera Health Company (SHC) is rated as a Buy due to its strong position in medical equipment sterilization, characterized by a vertically integrated model, high customer switching costs, and robust pricing power. The company exceeded Q2 2026 expectations and raised full-year guidance, trading at a discount to peers despite superior margins. While litigation risk from ethylene oxide lawsuits exists, improving leverage and strong free cash flow support the investment case.
Will Earnings Beat Change Sotera Health (SHC) Narrative
Sotera Health (SHC) recently reported strong Q2 2026 results, raising its full-year outlook due to gains in pricing, volume mix, and efficiency. Management is now exploring M&A, specifically for Sterigenics and other sterilization services, to boost its core earnings engine while navigating ongoing ethylene oxide regulatory and litigation challenges. The article discusses how this stronger guidance and M&A focus influence the existing investment narrative, which relies on volume growth and cash generation.
Piper Sandler Maintains Sotera Health Company(SHC.US) With Buy Rating, Maintains Target Price $25
Piper Sandler has reiterated its Buy rating on Sotera Health Company (SHC.US), maintaining a target price of $25. This indicates the firm's continued positive outlook on the company's stock performance and valuation.
Piper Sandler reiterates Sotera Health stock rating on growth outlook By Investing.com
Piper Sandler has reiterated an Overweight rating and a $25.00 price target for Sotera Health (NASDAQ: SHC) following investor meetings. The firm highlighted new CEO Alton Shader's growth vision, strong performance from Sterigenics, and plans to accelerate profitable growth and pursue M&A. Despite the stock trading near its 52-week high, InvestingPro analysis suggests it is currently overvalued relative to its Fair Value.
Sotera Health Reports Strong Q2 2026 Results, Raises Full-Year Outlook
Sotera Health reported strong Q2 2026 financial results, with net revenue increasing by 9.2% year-over-year and net income rising significantly to $54 million. The company also raised its full-year 2026 outlook for both net revenues and Adjusted EBITDA, reflecting confidence in continued growth across all business units. Despite past litigation and ongoing debt, Sotera Health achieved its long-term Net Leverage Ratio target and highlighted improved operational efficiency.
Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
Sotera Health Company (SHC) reported strong second-quarter results, with earnings of $0.26 per share, surpassing the Zacks Consensus Estimate of $0.24, and revenues of $321.38 million, beating the estimate by 3.29%. The company has consistently outperformed EPS and revenue estimates over the past four quarters. Despite outperforming expectations, SHC's stock has lagged the S&P 500 this year, holding a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.
Bank of America Corp DE Buys 991,620 Shares of Sotera Health Company $SHC
Bank of America Corp DE significantly increased its stake in Sotera Health Company (NASDAQ:SHC) by 332.7% in the first quarter, purchasing an additional 991,620 shares. This institutional activity comes amidst other large investors also modifying their holdings and recent insider selling transactions by Sotera Health executives. The company recently reported strong Q2 earnings, beating analyst estimates, and has received "Buy" and "Overweight" ratings from several Wall Street analysts, with an average price target of $21.50.
Sotera Health Company(SHC.US) Officer Sells US$21.17 Million in Common Stock
An officer at Sotera Health Company (SHC.US) has sold US$21.17 million worth of common stock. This significant insider transaction indicates a divestment of shares by a key individual within the company. The sale could be of interest to investors monitoring insider activity as an indicator of company prospects.
Insider Selling: Sotera Health (NASDAQ:SHC) Chairman Sells 850,000 Shares
Sotera Health (NASDAQ:SHC) Chairman Michael Petras sold 850,000 shares of the company's stock for over $15.7 million, reducing his direct ownership by 17.64%. Despite this insider selling, the stock rose 2.6% to $19.00, near its 52-week high, after beating quarterly earnings and revenue estimates. Analysts maintain a "Moderate Buy" consensus with an average price target of $21.50.
Sotera Health (NASDAQ: SHC) affiliate eyes $21.6M stock sale
An affiliate of Sotera Health (NASDAQ: SHC) has filed a Form 144, indicating its intention to sell up to 1.14 million shares of common stock, valued at approximately $21.6 million. The sale is planned for around August 17, 2026, through J.P. Morgan Securities LLC on NASDAQ. These shares were acquired through executive compensation awards and a transfer associated with Michael B. Petras, Jr.
State of Wyoming Buys Shares of 56,651 Sotera Health Company $SHC
The State of Wyoming acquired 56,651 shares of Sotera Health Company (NASDAQ:SHC) in the second quarter, valued at approximately $1 million. This comes as Sotera Health exceeded its quarterly earnings expectations with $0.26 EPS and $321.38 million in revenue, while institutional investors now own 91.03% of the company. Analysts maintain a "Moderate Buy" rating with an average price target of $21.50, despite an insider selling 150,000 shares.
Sotera Health president Rutz sells $2.83m in common stock
Michael P. Rutz, President of Sterigenics (a Sotera Health Co subsidiary), sold 150,000 shares of company stock for approximately $2.83 million on August 7, 2026. This sale occurred while the stock was trading near its 52-week high. The company recently reported strong Q2 2026 earnings, surpassing expectations, and raised its full-year outlook.
Sotera Health (SHC): Sessa Capital discloses 27M-share, 9.5% ownership position
Sessa Capital IM, L.P. and John Petry have disclosed a beneficial ownership of 27,050,000 shares of Sotera Health Co (SHC) common stock, representing a 9.5% stake. This information was reported on an amended Schedule 13G filing, indicating shared voting and dispositive power over these shares. The ownership percentage is calculated based on 285,166,994 shares outstanding after an offering on May 12, 2026.
Sotera Health Company’s Q2 Earnings Call: Our Top 5 Analyst Questions
Sotera Health Company reported strong Q2 CY2026 results, exceeding analyst expectations for revenue, adjusted EPS, and adjusted EBITDA, driven by growth in Sterigenics and Nordion, and improved customer engagement at Nelson Labs. Management raised full-year guidance, attributing confidence to new capacity and customer onboarding. Key analyst questions focused on growth drivers, CEO priorities, differentiation, guidance confidence, and a litigation/outsourcing update, all addressed positively by the leadership team.
Sotera Health (SHC): Sculptor Capital discloses 24M-share, 8.41% ownership stake
Sculptor Capital LP and its related entities have reported a beneficial ownership stake of 8.41% in Sotera Health Company (SHC), totaling 24,000,000 common shares. This disclosure, made via an amended Schedule 13G filing, indicates shared voting and dispositive power over these shares. The ownership percentage is based on Sotera's 285,374,795 common shares outstanding as of August 6, 2026.
Sotera Health announces resignation of director James C. Neary
Sotera Health (NASDAQ:SHC) announced the resignation of James C. Neary from its Board of Directors, effective Thursday. The company clarified that Neary's resignation was not due to any disagreements with Sotera Health's operations, policies, or practices. Following this, the Board's size will be set at eleven directors.
Sotera Health announces resignation of director James C. Neary
Sotera Health (NASDAQ:SHC) announced the resignation of James C. Neary from its Board of Directors, effective Thursday. The company clarified that his resignation was not due to any disagreements regarding its operations. This news follows Sotera Health's strong second-quarter financial results, where it surpassed Wall Street expectations for earnings and revenue, leading to raised full-year 2026 guidance.
Sotera Health Company (SHC): Buy, Sell, or Hold Post Q2 Earnings?
Sotera Health Company (SHC) has gained 11.3% over the last six months, slightly underperforming the S&P 500. Analysts are not recommending SHC due to slow organic growth, limited distribution channels for a small company in a scale-dependent industry, and breakeven free cash flow constraining reinvestment potential. The article suggests there are better investment opportunities available despite SHC not being a "terrible business."
President of Sterigenics U.S. Of Sotera Health Sold 37% Of Their Shares
The President of Sterigenics U.S., Michael Rutz, recently sold 37% of his shares in Sotera Health Company (NASDAQ:SHC) for approximately US$2.8 million. This sale follows another significant insider sale by the Executive Chairman of the Board, Michael Petras, worth US$12 million over the past year. Despite these sales, insiders still own 2.4% of the company, valued at US$131 million, suggesting management incentives are aligned with shareholders, though the repeated sales raise some concerns.
Sotera Health Company’s Q2 Earnings Call: Our Top 5 Analyst Questions
Sotera Health reported strong Q2 2026 results with broad-based growth across its business units, exceeding analyst estimates for revenue, EPS, and EBITDA, and subsequently raising its full-year guidance. The article highlights five key analyst questions from the earnings call, focusing on drivers of Nelson Labs' performance, the new CEO's priorities, Sterigenics' growth differentiation, confidence in raised guidance, and a litigation/outsourcing update. The company is looking forward to the ramp-up of new X-ray sterilization capacity and the onboarding of a large outsourcing customer.
Sotera Health (NASDAQ:SHC) Insider Sells $2,826,000.00 in Stock
Sotera Health insider Michael Rutz sold 150,000 shares of the company's stock for $2,826,000.00, reducing his position by nearly 31%. This sale follows strong quarterly results where the company beat EPS estimates and saw revenue increase by 9.2% year-over-year. Analysts have maintained a "Moderate Buy" rating for SHC, with several price target increases.
Sotera Health (SHC) Is Getting Attention Again, What Is Behind It?
Sotera Health (SHC) is gaining attention after reporting higher Q2 2026 revenue of US$321.38 million and net income of US$53.64 million, leading to a 22.23% 90-day share price return. Analysts generally view the stock as undervalued with a consensus price target of $20.22, though a discounted cash flow model suggests an even higher fair value of $28.53, despite ongoing risks from compliance, litigation, and competition.
3 Healthcare Stocks with Open Questions
This article identifies three healthcare stocks—Sotera Health Company (SHC), Gilead Sciences (GILD), and Myriad Genetics (MYGN)—that investors should approach with caution despite the broader healthcare industry's growth. The author highlights specific concerns for each company, including underperforming core businesses, lagging sales growth, and financial challenges, suggesting that these factors may hinder their future performance.
Quantinno Capital Management LP Has $2.83 Million Position in Sotera Health Company $SHC
Quantinno Capital Management LP significantly reduced its stake in Sotera Health Company (SHC) by 85.9% in the first quarter, selling over 1.2 million shares but still retaining a $2.83 million position. Despite this sale, institutional ownership in Sotera Health remains high at 91.03%, with other funds increasing their stakes. The company recently reported strong quarterly earnings and revenue that exceeded analyst expectations, leading to several analysts raising their price targets, although concerns about debt and litigation persist.
Sotera Health (SHC) Is Getting Attention Again, What Is Behind It?
Sotera Health (SHC) has gained renewed attention following its Q2 2026 earnings, reporting increased revenue and net income. The stock has shown strong recent performance, with a 22.23% 90-day return and a 35.00% one-year return. Analysts have a consensus price target of $20.22, suggesting the stock is slightly undervalued, while a DCF model indicates a higher fair value of $28.53.
Sotera Health (SHC) Stock Trails Profit Surge As Legal Risks Linger
Sotera Health (SHC) recently reported strong Q2 2026 earnings, with significant increases in revenue and net income, yet its stock price barely moved due to lingering legal risks, heavy capital spending, and past insider selling. The company's operating performance, particularly in its sterilization and lab platforms, supports a bull case, but ongoing litigation in Georgia and California and substantial capex weigh on investor sentiment. Despite improved margins and earnings momentum, the market remains cautious given these unresolved issues.
Sotera Health (SHC) Stock Trails Profit Surge As Legal Risks Linger
Sotera Health (SHC) recently reported strong Q2 2026 earnings with significant revenue and EPS growth, and improved margins, yet its stock slipped slightly. Despite operational strengths like pricing power and capacity additions in its sterilization and lab platforms, the company faces ongoing concerns including modest organic growth, heavy capital expenditure, and persistent legal risks from active litigation in Georgia and California. These factors contribute to a cautious sentiment among investors, even with robust financial performance.
Piper Sandler Maintains Sotera Health Company(SHC.US) With Buy Rating, Raises Target Price to $25
Piper Sandler has reiterated its "Buy" rating for Sotera Health Company (SHC.US) and increased the target price to $25. This indicates a positive outlook from the analyst firm regarding the company's future performance.
GUIDANCE: (SHC) Sotera Health Expects Full Year 2026 Revenue Range $1.24B - $1.25B, Vs. FactSet Est of $1.24B
Sotera Health (SHC) has provided its revenue guidance for the full year 2026, expecting it to fall within the range of $1.24 billion to $1.25 billion. This forecast aligns closely with FactSet's estimated revenue of $1.24 billion for the same period. The guidance offers insight into the company's financial projections for the upcoming years.
Sotera Health Company Stock 12‑Month Price Target Raised to $21.44, Implies 19% Upside
Sotera Health Company (SHC) has seen its average 12-month price target raised from $20.44 to $21.44 by analysts, implying a 19% potential upside based on its closing price on August 5th. The consensus rating among 10 analysts remains a "Buy," with 8 recommending Buy and 2 recommending Hold.
Sotera Health (SHC) Is Up 5.9% After Q2 Earnings Beat And Guidance Hike What’s Changed
Sotera Health (SHC) saw its stock rise by 5.9% following a strong Q2 2026 earnings report, where revenue increased to US$321.38 million and net income hit US$53.64 million. The company's management also raised its full-year guidance due to broad-based growth across its Sterigenics, Nordion, and Nelson Labs segments. While the improved outlook supports short-term margin improvement, the article notes that risks related to ethylene oxide regulations and litigation persist.
Sotera Health Co 2026: Revenue $321.38M, EPS $0.19— 10-Q Summary
Sotera Health Co (SHC) reported strong second-quarter 2026 results, with revenue reaching $321.38 million and diluted EPS of $0.19. The company saw significant year-over-year improvement across all key financial metrics, driven by higher service pricing and a favorable product mix. Despite ongoing expenses related to ethylene oxide remediation, management is confident in the company's ability to support growth through operational capacity expansion and strategic investments.
Sotera Health (NASDAQ:SHC) Beats Q2 Estimates and Raises Guidance, But Shares Slip
Sotera Health (SHC) exceeded analyst expectations for its second-quarter earnings and revenue, reporting $0.26 adjusted EPS and $321.4 million in net revenues. The company also raised its full-year guidance for net revenues and adjusted EPS, and improved its net leverage to 3.0 times. Despite the strong results and positive outlook, SHC shares experienced a slight slip, potentially due to profit-taking or ongoing litigation costs related to its ethylene oxide sterilization facilities.
Will Sotera Health's (SHC) Sharp Profit Rebound and Higher EPS Rewrite Its Turnaround Narrative?
Sotera Health (SHC) reported a significant profit rebound in Q2 2026, with net income rising to US$53.64 million and EPS to US$0.19, shifting from a net loss in the first half of the year. This turnaround in profitability is a key catalyst for its investment narrative, though the company still faces challenges including ethylene oxide litigation and the need for consistent execution to meet its reaffirmed 2026 revenue guidance of US$1.233 billion to US$1.251 billion.
Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
Sotera Health Company (SHC) reported strong Q2 2026 earnings, beating analyst estimates for both EPS ($0.26 vs. $0.24) and revenue ($321.38 million vs. $310.27 million). This marks the fourth consecutive quarter the company has surpassed both earnings and revenue expectations. Despite this positive performance, SHC shares have underperformed the S&P 500 year-to-date, and the stock currently holds a Zacks Rank #3 (Hold).
Sotera Health Company (NASDAQ:SHC) Surprises With Strong Q2 CY2026
Sotera Health (NASDAQ:SHC) reported strong Q2 CY2026 results, exceeding revenue and adjusted EPS expectations with sales up 9.2% year-on-year to $321.4 million. The company slightly increased its full-year revenue and Adjusted EPS guidance, demonstrating focused execution across its business units. Despite a mediocre 6.7% compounded annual growth rate over the last five years, recent performance shows an increase in demand, with organic revenue growing 8% year-on-year in Q2.
Earnings Flash (SHC) Sotera Health Company Reports Q2 Revenue $321.4M, vs. FactSet Est of $309.7M
Sotera Health Company (SHC) announced its Q2 revenue of $321.4 million, surpassing FactSet's estimate of $309.7 million. The company also reported Q2 adjusted EPS of $0.26 per share, exceeding the FactSet estimate of $0.24 per share. Following these results, Sotera Health has lifted the lower end of its 2026 guidance.
Sotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Sotera Health (SHC) reported strong Q2 2026 earnings, with revenue up 9.2% year-over-year to $321.38 million and EPS at $0.26. The company surpassed Zacks Consensus Estimates for both revenue and EPS, showing a surprise of +3.29% and +8.33% respectively. Key segment metrics for Sterigenics, Nelson Labs, and Nordion also exceeded analyst expectations, indicating solid financial health and contributing to the company's positive performance.
Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
Sotera Health Company (SHC) reported strong Q2 earnings, beating the Zacks Consensus Estimate with $0.26 per share and revenues of $321.38 million. This marks the fourth consecutive quarter the company has surpassed both EPS and revenue expectations. Despite this performance, SHC's stock has underperformed the S&P 500 this year, holding a Zacks Rank #3 (Hold) with a mixed estimate revisions trend.
Sotera Health earnings loom as investors eye new CEO’s execution By Investing.com
Sotera Health is set to report its second-quarter results, with investors keenly watching the performance under new CEO Alton Shader. Analysts anticipate a 33% increase in profit and an 11% jump in sales from the prior quarter, driven by strong market tailwinds in sterilization services. The report will assess Shader's execution, revenue growth trajectory, and margin performance as the company navigates leadership changes in a competitive yet expanding market.
Sotera Health Company (SHC) Q2 Earnings Report Preview: What To Look For
Sotera Health (NASDAQ:SHC) is set to report its Q2 earnings this Thursday before market hours. The company had a strong previous quarter, beating revenue expectations and meeting EPS estimates. Analysts anticipate a 5.2% year-on-year revenue growth for Q2, with expectations generally reconfirmed over the last 30 days.
SOTERA HEALTH COMPANY (SHC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of The Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Sotera Health Company (SHC)
Bernstein Liebhard LLP has issued a shareholder class action alert for investors in Sotera Health Company (SHC), reminding them of the March 27, 2023 deadline to file a lead plaintiff motion. The lawsuit alleges violations of securities laws related to misleading representations about Sotera's EtO emissions controls and liability exposure, which led to artificial inflation of stock prices. This follows a jury finding Sotera liable for cancer caused by its Illinois facility's emissions, resulting in a significant stock price decline and analyst downgrades.
Sotera Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Sotera Health Company (NASDAQ: SHC) and reminds investors of the March 27, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Sotera made false and misleading representations regarding its emissions control systems and exposure to liability from lawsuits concerning harmful Ethylene Oxide (EtO) emissions, which caused its stock price to decline significantly after a jury found the company liable for a plaintiff's cancer. Investors who suffered losses exceeding $100,000 are encouraged to contact the firm.
Precision Trading with Sotera Health Company (SHC) Risk Zones
This article provides a detailed analysis of Sotera Health Company (SHC) using AI models to suggest precision trading strategies. It highlights a strong near-term sentiment for SHC, a mid-channel oscillation pattern, and an exceptional risk-reward short setup. The analysis includes institutional trading strategies tailored for different risk profiles, multi-timeframe signal analysis, and AI-generated signals for support and resistance levels.
Sotera Health Number of Employees 2026 | Employee Count & Headcount Data
Sotera Health Co. (SHC) had approximately 3,026 employees worldwide as of March 2026, representing a 5.0% growth since 2023. The company, headquartered in Broadview Heights, Ohio, is actively hiring, with 124 job postings in 2026. Sotera Health's workforce is concentrated in North America and its average salary is $70,878, though employee sentiment is reported as negative and declining.
